CAMBRIDGE, UK—A new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui and colleagues from the Cancer Research UK Cambridge Institute, University of Cambridge, report in the New England Journal of Medicine that circulating tumour DNA is a more powerful marker of breast cancer progression than using blood tests for cancer cells or antigens, and raises the possibility of screening the effectiveness of drugs in days rather than months needed to wait for a change in radiological appearance.
You may also like...
Non Communicable Diseases: Crisis For Low And Middle Income Countries 12 Nov, 2011 Rio Conference on Sustainable Development: “Health Should Be Top Priority” 7 Oct, 2012 Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer 11 Feb, 2014 Audio Journal of Oncology with Oncology Times, June 2013 13 Jun, 2013
- Previous story Circulating free tumour DNA test could guide breast cancer therapy
- Next story Two-step immunotherapy brings promise in advanced ovarian cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014